Trials / Completed
CompletedNCT01478191
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
Prognosis of Patients With Relapsed/Refractory Hl Treated With Combination of Ifosfamide, Gemcitabine and Vinorelbine(IGEV) Induction Therapy Before High-dose Chemotherapy (HDCT) With Autologous Hematopoietic Stem Cells Transplantation (AHSCT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 495 (estimated)
- Sponsor
- Fondazione Italiana Linfomi - ETS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective analysis of a homogeneous cohort of patients with relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for reassess the most common prognostic factors and try to identify a prognostic score with clinical and therapeutic relevance by using 6 clinical tools: 1. B symptoms(yes/no) 2. relapse in previously irradiated areas(yes/no) 3. Ann Arbor Stage (III/IV vs I/II) 4. disease status at accrual (refractory vs relapsed) 5. Early relapse within 12 months of Complete Response (CR) versus late relapse after Complete Response (CR) lasting \> l2 months", 6. extranodal involvement (yes/no).
Conditions
Timeline
- Start date
- 2010-05-01
- Completion
- 2011-06-01
- First posted
- 2011-11-23
- Last updated
- 2013-03-06
Locations
40 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01478191. Inclusion in this directory is not an endorsement.